Clinical trial
A Randomized, Double Blind Trial of LdT (Telbivudine) Versus Lamivudine in…
NCT00057265 · Novartis, Industry · Completed
Key facts
| NCT number | NCT00057265 |
|---|---|
| Title | A Randomized, Double Blind Trial of LdT (Telbivudine) Versus Lamivudine in Adults With Compensated Chronic Hepatitis B |
| Official title | A Randomized, Double Blind Trial of LdT (Telbivudine) Versus Lamivudine in Adults With Compensated Chronic Hepatitis B |
| Lead sponsor | Novartis, Industry |
| Collaborators | Novartis Pharmaceuticals Industry |
| Status | Completed |
| Phase | Phase 3 |
| Study type | Interventional |
| Conditions | Chronic Hepatitis B |
| Intervention type | Drug |
| Interventions | telbivudine or lamivudine |
| Start date | Feb 1, 2003 |
| Primary completion | Apr 1, 2006 |
| First posted | Mar 31, 2003 |
| Last update posted | Mar 20, 2015 |
| Countries | South Korea, Spain, Thailand, Turkey (Türkiye), United Kingdom, United States |
At a glance
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: